Myovant_Logo_FullColor_RGB4.png
Myovant Sciences to Host Third Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on February 11, 2021
January 29, 2021 08:30 ET | Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and...
Myovant_Logo_FullColor_RGB4.png
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
January 26, 2021 06:55 ET | Myovant Sciences, Inc.
84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year82.8% average reduction from baseline on the Numerical...
Myovant_Logo_FullColor_RGB4.png
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
January 20, 2021 08:30 ET | Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 20, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity...
Myovant_Logo_FullColor_RGB4.png
CORRECTION -- Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021 14:57 ET | Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Myovant Sciences (NYSE: MYOV), please note that in the first paragraph of the...
Myovant_Logo_FullColor_RGB4.png
Myovant Sciences to Present at the 39th Annual J.P. Morgan Healthcare Conference
January 05, 2021 08:30 ET | Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that David Marek, chief...
Myovant_Logo_FullColor_RGB4.png
Myovant Sciences Announces U.S. Availability of ORGOVYX™ for the Treatment of Advanced Prostate Cancer
January 05, 2021 06:58 ET | Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that ORGOVYX™ (relugolix),...
Myovant_Logo_FullColor_RGB4.png
Myovant Sciences Appoints Industry Veteran David Marek as Chief Executive Officer
January 04, 2021 06:58 ET | Myovant Sciences, Inc.
BASEL, Switzerland, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of David...
Myovant_Logo_FullColor_RGB4.png
Myovant Sciences and Pfizer Announce Collaboration to Develop and Commercialize Relugolix in Oncology and Women’s Health
December 28, 2020 06:30 ET | Myovant Sciences, Inc.
Myovant and Pfizer to jointly develop and commercialize ORGOVYX™ (relugolix) and relugolix combination tablet and share profits and expenses in the U.S. and CanadaMyovant to receive an upfront payment...
Myovant logo_GNW.jpg
Myovant Sciences Announces FDA Approval of ORGOVYX™ (relugolix), the First and Only Oral Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist for Advanced Prostate Cancer
December 18, 2020 16:49 ET | Myovant Sciences, Inc.
ORGOVYX demonstrated a 96.7% response rate in testosterone suppression to castrate levels (< 50 ng/dL) through 48 weeks in the Phase 3 HERO studyConference call and webcast to be held on December...
Myovant logo_GNW.jpg
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
December 16, 2020 08:30 ET | Myovant Sciences, Inc.
BASEL, Switzerland, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced that it approved equity...